Compare AbbVie Inc (ABBV) vs Zillow Group Inc Class C (Z) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

Zillow Group (Z) trades at $33.61, up 0.54% on the day, amid a challenging real estate market. The stock faces a bearish technical signal with support at $33 and resistance at $34. Fundamentally, the company shows improving revenue and a return to profitability in 2025, with a net income of $23 million, though valuation ratios like a P/E of 146.74 remain high. Recent news is dominated by a securities class action lawsuit with a deadline of August 10, 2026, creating significant headline risk.

The outlook is cautious. While analyst consensus is a Buy with a $47.00 price target, indicating potential upside, near-term risks from the lawsuit and a bearish technical picture suggest volatility. Investment opportunity hinges on the company's ability to sustain revenue growth and improve margins, but investors must weigh the legal overhang and high valuation against the positive earnings trajectory.